Q-omics provides the consensus-scored FOXB2 profile across patient tissues and cancer cell-line models. FOXB2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FOXB2 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, FOXB2 RNA expression shows 8,440 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where FOXB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXB2 survival associations across molecular data types. FOXB2 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXB2 RNA expression–survival associations across cancer types. High FOXB2 expression shows unfavorable associations in KICH, LIHC, KIRP, MESO and ACC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify KICH as the clearest survival context for FOXB2 RNA expression.
This table summarizes FOXB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FOXB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXB2 shows lower tumor expression in UCEC and higher tumor expression in KIRC, PRAD, LUSC and KIRP. The KIRC box plot shows higher FOXB2 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .001).
This table shows molecular features associated with FOXB2 in patient tissues and cancer cell lines. In patient samples, FOXB2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
